Moderna’s stock falls 4% as CEO says enrollment in vaccine trial has been slowed to ensure diversity

This post was originally published on this site

Shares of Moderna Inc. MRNA, -3.48% were down 4.6% in trading on Friday after the company’s CEO told CNBC that it was slowing down enrollment in the Phase 3 clinical trial for its experimental COVID-19 vaccine to ensure diversity of the study’s …

Click here to read full article